ASX - By Stock
|
TLX |
Re:
US Insurance companies denying coverage for Illucix
|
|
89zirconium
|
22 |
6.9K |
0 |
02/07/22 |
02/07/22 |
ASX - By Stock
|
22
|
6.9K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
US Insurance companies denying coverage for Illucix
|
|
89zirconium
|
22 |
6.9K |
1 |
02/07/22 |
02/07/22 |
ASX - By Stock
|
22
|
6.9K
|
1
|
|
ASX - By Stock
|
TLX |
Re:
US Insurance companies denying coverage for Illucix
|
|
89zirconium
|
22 |
6.9K |
1 |
01/07/22 |
01/07/22 |
ASX - By Stock
|
22
|
6.9K
|
1
|
|
ASX - By Stock
|
TLX |
Re:
US Insurance companies denying coverage for Illucix
|
|
89zirconium
|
22 |
6.9K |
0 |
01/07/22 |
01/07/22 |
ASX - By Stock
|
22
|
6.9K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
News: TLX Telix, Invicro Advance AI Partnership
|
|
89zirconium
|
11 |
3.5K |
0 |
15/06/22 |
15/06/22 |
ASX - By Stock
|
11
|
3.5K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
News: TLX Telix, Invicro Advance AI Partnership
|
|
89zirconium
|
11 |
3.5K |
1 |
15/06/22 |
15/06/22 |
ASX - By Stock
|
11
|
3.5K
|
1
|
|
ASX - By Stock
|
TLX |
Re:
How big will 177Lu - PSMA be?
|
|
89zirconium
|
28 |
11K |
0 |
15/06/22 |
15/06/22 |
ASX - By Stock
|
28
|
11K
|
0
|
|
ASX - By Stock
|
TLX Biotech |
Re:
Jubilant Radiopharma Joins Illuccix® Pharmacy Partner Network
|
|
89zirconium
|
6 |
2.1K |
0 |
14/06/22 |
14/06/22 |
ASX - By Stock
|
6
|
2.1K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
News: TLX Telix, Invicro Advance AI Partnership
|
|
89zirconium
|
11 |
3.5K |
0 |
14/06/22 |
14/06/22 |
ASX - By Stock
|
11
|
3.5K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
News: TLX Telix, Invicro Advance AI Partnership
|
|
89zirconium
|
11 |
3.5K |
0 |
14/06/22 |
14/06/22 |
ASX - By Stock
|
11
|
3.5K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
News: TLX Telix, Invicro Advance AI Partnership
|
|
89zirconium
|
11 |
3.5K |
0 |
14/06/22 |
14/06/22 |
ASX - By Stock
|
11
|
3.5K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
News: TLX Telix, Invicro Advance AI Partnership
|
|
89zirconium
|
11 |
3.5K |
0 |
14/06/22 |
14/06/22 |
ASX - By Stock
|
11
|
3.5K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
How big will 177Lu - PSMA be?
|
|
89zirconium
|
28 |
11K |
0 |
13/06/22 |
13/06/22 |
ASX - By Stock
|
28
|
11K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
How big will 177Lu - PSMA be?
|
|
89zirconium
|
28 |
11K |
1 |
13/06/22 |
13/06/22 |
ASX - By Stock
|
28
|
11K
|
1
|
|
ASX - By Stock
|
TLX |
Re:
How big will 177Lu - PSMA be?
|
|
89zirconium
|
28 |
11K |
1 |
12/06/22 |
12/06/22 |
ASX - By Stock
|
28
|
11K
|
1
|
|
ASX - By Stock
|
TLX |
Re:
Competition
|
|
89zirconium
|
254 |
116K |
0 |
31/05/22 |
31/05/22 |
ASX - By Stock
|
254
|
116K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
News Article
|
|
89zirconium
|
26 |
11K |
0 |
31/05/22 |
31/05/22 |
ASX - By Stock
|
26
|
11K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Trading Halt
|
|
89zirconium
|
36 |
15K |
1 |
31/05/22 |
31/05/22 |
ASX - By Stock
|
36
|
15K
|
1
|
|
ASX - By Stock
|
TLX |
Re:
Competition
|
|
89zirconium
|
254 |
116K |
1 |
31/05/22 |
31/05/22 |
ASX - By Stock
|
254
|
116K
|
1
|
|
ASX - By Stock
|
TLX |
Re:
Competition
|
|
89zirconium
|
254 |
116K |
1 |
31/05/22 |
31/05/22 |
ASX - By Stock
|
254
|
116K
|
1
|
|
ASX - By Stock
|
TLX |
Re:
The China conection
|
|
89zirconium
|
15 |
5.6K |
1 |
30/05/22 |
30/05/22 |
ASX - By Stock
|
15
|
5.6K
|
1
|
|
ASX - By Stock
|
TLX |
Re:
The China conection
|
|
89zirconium
|
15 |
5.6K |
1 |
30/05/22 |
30/05/22 |
ASX - By Stock
|
15
|
5.6K
|
1
|
|
ASX - By Stock
|
TLX |
Re:
The China conection
|
|
89zirconium
|
15 |
5.6K |
1 |
30/05/22 |
30/05/22 |
ASX - By Stock
|
15
|
5.6K
|
1
|
|
ASX - By Stock
|
TLX |
Re:
Overall Survival figures TheraP Trial - A tie between Lu177 v Cabazitaxel
|
|
89zirconium
|
5 |
1.8K |
3 |
28/05/22 |
28/05/22 |
ASX - By Stock
|
5
|
1.8K
|
3
|
|
ASX - By Stock
|
TLX |
Re:
Competition
|
|
89zirconium
|
254 |
116K |
1 |
28/05/22 |
28/05/22 |
ASX - By Stock
|
254
|
116K
|
1
|
|
ASX - By Stock
|
TLX |
Re:
Competition
|
|
89zirconium
|
254 |
116K |
0 |
27/05/22 |
27/05/22 |
ASX - By Stock
|
254
|
116K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
Ann: 2021 Full Year Results Presentation
|
|
89zirconium
|
9 |
6.4K |
4 |
26/05/22 |
26/05/22 |
ASX - By Stock
|
9
|
6.4K
|
4
|
|
ASX - By Stock
|
TLX |
Re:
The PRIMARY Score: PSMA PET/CT prostate cancer diagnosis.
|
|
89zirconium
|
9 |
3.9K |
2 |
25/05/22 |
25/05/22 |
ASX - By Stock
|
9
|
3.9K
|
2
|
|
ASX - By Stock
|
TLX |
Re:
The PRIMARY Score: PSMA PET/CT prostate cancer diagnosis.
|
|
89zirconium
|
9 |
3.9K |
3 |
25/05/22 |
25/05/22 |
ASX - By Stock
|
9
|
3.9K
|
3
|
|
ASX - By Stock
|
TLX |
Re:
Competition
|
|
89zirconium
|
254 |
116K |
1 |
25/05/22 |
25/05/22 |
ASX - By Stock
|
254
|
116K
|
1
|
|
ASX - By Stock
|
TLX |
Re:
Competition
|
|
89zirconium
|
254 |
116K |
0 |
25/05/22 |
25/05/22 |
ASX - By Stock
|
254
|
116K
|
0
|
|
ASX - By Stock
|
TLX Biotech |
Re:
Carbonic Anhydrase IX-Targeted α-Radionuclide Therapy w/ 225Ac Inhibits Tumor Growth in Renal Cell Carc. Model
|
|
89zirconium
|
4 |
1.8K |
0 |
25/05/22 |
25/05/22 |
ASX - By Stock
|
4
|
1.8K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
Competition
|
|
89zirconium
|
254 |
116K |
0 |
25/05/22 |
25/05/22 |
ASX - By Stock
|
254
|
116K
|
0
|
|
ASX - By Stock
|
TLX Biotech |
Re:
Carbonic Anhydrase IX-Targeted α-Radionuclide Therapy w/ 225Ac Inhibits Tumor Growth in Renal Cell Carc. Model
|
|
89zirconium
|
4 |
1.8K |
0 |
25/05/22 |
25/05/22 |
ASX - By Stock
|
4
|
1.8K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
My analysis and intrinsic value of TLX March 2022
|
|
89zirconium
|
82 |
42K |
0 |
25/05/22 |
25/05/22 |
ASX - By Stock
|
82
|
42K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
My analysis and intrinsic value of TLX March 2022
|
|
89zirconium
|
82 |
42K |
0 |
25/05/22 |
25/05/22 |
ASX - By Stock
|
82
|
42K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
My analysis and intrinsic value of TLX March 2022
|
|
89zirconium
|
82 |
42K |
2 |
25/05/22 |
25/05/22 |
ASX - By Stock
|
82
|
42K
|
2
|
|
ASX - By Stock
|
TLX |
Re:
My analysis and intrinsic value of TLX March 2022
|
|
89zirconium
|
82 |
42K |
0 |
24/05/22 |
24/05/22 |
ASX - By Stock
|
82
|
42K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
My analysis and intrinsic value of TLX March 2022
|
|
89zirconium
|
82 |
42K |
0 |
24/05/22 |
24/05/22 |
ASX - By Stock
|
82
|
42K
|
0
|
|
ASX - By Stock
|
TLX Biotech |
Re:
Chief Medical Officer, Dr. Colin Hayward, Discussion with Wilsons Advisory
|
|
89zirconium
|
2 |
1.1K |
1 |
22/05/22 |
22/05/22 |
ASX - By Stock
|
2
|
1.1K
|
1
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Chairman's Address to Annual General Meeting
|
|
89zirconium
|
23 |
6.1K |
0 |
21/05/22 |
21/05/22 |
ASX - By Stock
|
23
|
6.1K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Chairman's Address to Annual General Meeting
|
|
89zirconium
|
23 |
6.1K |
0 |
21/05/22 |
21/05/22 |
ASX - By Stock
|
23
|
6.1K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Chairman's Address to Annual General Meeting
|
|
89zirconium
|
23 |
6.1K |
0 |
21/05/22 |
21/05/22 |
ASX - By Stock
|
23
|
6.1K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Chairman's Address to Annual General Meeting
|
|
89zirconium
|
23 |
6.1K |
0 |
21/05/22 |
21/05/22 |
ASX - By Stock
|
23
|
6.1K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Chairman's Address to Annual General Meeting
|
|
89zirconium
|
23 |
6.1K |
1 |
21/05/22 |
21/05/22 |
ASX - By Stock
|
23
|
6.1K
|
1
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Chairman's Address to Annual General Meeting
|
|
89zirconium
|
23 |
6.1K |
3 |
21/05/22 |
21/05/22 |
ASX - By Stock
|
23
|
6.1K
|
3
|
|
ASX - By Stock
|
TLX |
Re:
Ann: ZIRCON Phase 3 Renal Cancer Imaging Study - Progress Update
|
|
89zirconium
|
11 |
5.5K |
2 |
18/05/22 |
18/05/22 |
ASX - By Stock
|
11
|
5.5K
|
2
|
|
ASX - By Stock
|
TLX |
Re:
Ann: 2022 AGM Notice of Meeting, Proxy Form and Online Guide
|
|
89zirconium
|
7 |
2.2K |
0 |
16/05/22 |
16/05/22 |
ASX - By Stock
|
7
|
2.2K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
Ann: 2022 AGM Notice of Meeting, Proxy Form and Online Guide
|
|
89zirconium
|
7 |
2.2K |
0 |
16/05/22 |
16/05/22 |
ASX - By Stock
|
7
|
2.2K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
How low will it go?
|
|
89zirconium
|
132 |
59K |
0 |
16/05/22 |
16/05/22 |
ASX - By Stock
|
132
|
59K
|
0
|
|